DHR vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DHR and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DHR | REGN |
|---|---|---|
| Company Name | Danaher Corporation | Regeneron Pharmaceuticals, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 149.76 billion USD | 59.52 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | December 29, 1978 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DHR and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DHR | REGN |
|---|---|---|
| 5-Day Price Return | 5.37% | 0.31% |
| 13-Week Price Return | 4.14% | -2.45% |
| 26-Week Price Return | -0.41% | -22.23% |
| 52-Week Price Return | -21.73% | -49.91% |
| Month-to-Date Return | 6.08% | 2.95% |
| Year-to-Date Return | -8.89% | -21.17% |
| 10-Day Avg. Volume | 3.84M | 1.11M |
| 3-Month Avg. Volume | 4.21M | 1.23M |
| 3-Month Volatility | 30.98% | 49.41% |
| Beta | 0.79 | 0.31 |
Profitability
Return on Equity (TTM)
DHR
6.69%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
DHR’s Return on Equity of 6.69% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
REGN
15.11%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
DHR
14.21%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
DHR’s Net Profit Margin of 14.21% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
REGN
31.37%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DHR
18.43%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
DHR’s Operating Profit Margin of 18.43% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
REGN
27.02%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | DHR | REGN |
|---|---|---|
| Return on Equity (TTM) | 6.69% | 15.11% |
| Return on Assets (TTM) | 4.28% | 11.81% |
| Net Profit Margin (TTM) | 14.21% | 31.37% |
| Operating Profit Margin (TTM) | 18.43% | 27.02% |
| Gross Profit Margin (TTM) | 59.72% | 86.46% |
Financial Strength
Current Ratio (MRQ)
DHR
1.62
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
DHR’s Current Ratio of 1.62 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
REGN
4.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
REGN
0.09
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
REGN
243.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | DHR | REGN |
|---|---|---|
| Current Ratio (MRQ) | 1.62 | 4.60 |
| Quick Ratio (MRQ) | 1.10 | 3.78 |
| Debt-to-Equity Ratio (MRQ) | 0.33 | 0.09 |
| Interest Coverage Ratio (TTM) | 22.31 | 243.95 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DHR
0.55%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.55% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
DHR
23.85%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 23.85% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | DHR | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.55% | 0.00% |
| Dividend Payout Ratio (TTM) | 23.85% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
DHR
43.76
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
DHR’s P/E Ratio of 43.76 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
REGN
13.20
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.20 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
DHR
6.22
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
DHR’s P/S Ratio of 6.22 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
REGN
4.14
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.14 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DHR
2.72
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
DHR’s P/B Ratio of 2.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
REGN
1.89
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | DHR | REGN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 43.76 | 13.20 |
| Price-to-Sales Ratio (TTM) | 6.22 | 4.14 |
| Price-to-Book Ratio (MRQ) | 2.72 | 1.89 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.72 | 16.55 |